NCT03624790View on ClinicalTrials.gov

Inpatient Challenge Study of rRSV A/Maryland/001/11, a Human Respiratory Syncytial Virus Challenge Strain, Administered to Healthy Adult Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2018

Primary Completion Date

October 24, 2024

Study Completion Date

October 24, 2024

Conditions

Respiratory Syncytial Virus Infections

Interventions

BIOLOGICAL

rRSV A/Maryland/001/11

10\^5 PFU; delivered intranasally

Trial Locations (1)

21205

Johns Hopkins Bloomberg School of Public Health, Baltimore

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03624790 - Inpatient Challenge Study of rRSV A/Maryland/001/11, a Human Respiratory Syncytial Virus Challenge Strain, Administered to Healthy Adult Volunteers | Biotech Hunter | Biotech Hunter